Dupilumab
Dupixent
Interleukin-4 Receptor alpha Antagonist
NADAC/unit
$1008.4070
No Shortage
Tier 1: 71.7%
PA Req: 398.5%
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose diseas....
vs. brand Dupixent: Generic saves up to -9984% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.